Lipoatrophy among HIV-infected patients is associated with higher levels of depression than lipohypertrophy

HIV Medicine

Volumn 9, Issue 9, 2008, Pages 780-786

  Crane, Heidi M ^a   Grunfeld, C ^b   Harrington, R D ^a   Uldall, K K ^a   Ciechanowski, P S ^a   Kitahata, M M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Depression; HIV; Lipoatrophy; Lipodystrophy; Lipohypertrophy

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIRETROVIRUS AGENT;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LINEAR REGRESSION ANALYSIS; LIPOATROPHY; LIPOHYPERTROPHY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SCORING SYSTEM; UNITED STATES;

ADULT; ANALYSIS OF VARIANCE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY FAT DISTRIBUTION; BODY IMAGE; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER; FEMALE; HIV INFECTIONS; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 54049143875     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00631.x     Document Type: Article

References (35)

1. Chen D, Misra A, Garg A. Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 2002; 87: 4845-4856.
2. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study. Arch Intern Med 2000; 160: 2050-2056.
3. Dukers NH, Stolte IG, Albrecht N, Coutinho RA, de Wit JB. The impact of experiencing lipodystrophy on the sexual behaviour and well-being among HIV-infected homosexual men. AIDS 2001; 15: 812-813.
4. Hays RD, Cunningham WE, Sherbourne CD et al. Health-related quality of life in patients with human immunodeficiency virus infection in the United States: Results from the HIV cost and services utilization study. Am J Med 2000; 108: 714-722.
5. Power R, Tate HL, McGill SM, Taylor C. A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV-positive individuals. Sex Transm Infect 2003; 79: 137-141.
6. Marin A, Casado JL, Aranzabal L et al. Validation of a specific questionnaire on psychological and social repercussions of the lipodystrophy syndrome in HIV-infected patients. Qual Life Res 2006; 15: 767-775.
7. Burgoyne R, Collins E, Wagner C et al. The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults. Qual Life Res 2005; 14: 981-990.
8. Steel JL, Landsittel D, Calhoun B, Wieand S, Kingsley LA. Effects of lipodystrophy on quality of life and depression in HIV-infected men on HAART. AIDS Patient Care STDS 2006; 20: 565-575.
9. Bacchetti P, Gripshover B, Grunfeld C et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005; 40: 121-131.
10. Fat Redistribution and Metabolic Change in HIV Infection (FRAM) Investigators. Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr 2006; 42: 562-571.
11. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med 2001; 16: 606-613.
12. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: The PHQ primary care study. Primary care evaluation of mental disorders. Patient health questionnaire. JAMA 1999; 282: 1737-1744.
13. Newcombe DA, Humeniuk RE, Ali R. Validation of the World Health Organization Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): Report of results from the Australian site. Drug Alcohol Rev 2005; 24: 217-226.
14. WHO ASSIST Working Group. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): Development, reliability and feasibility. Addiction 2002; 97: 1183-1194.
15. Gripshover B, Tien PC, Saag MS, Osmond D, Bacchetti P, Grunfeld C. Lipoatrophy is the dominant feature of the lipodystrophy syndrome in HIV-infected men. 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 2003 [Abstract 732].
16. Tien PC, Cole SR, Williams CM et al. Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study. J Acquir Immune Defic Syndr 2003; 34: 461-466.
17. Crane HM, Lober W, Webster E et al. Routine collection of patient-reported outcomes in an HIV clinic setting: The first 100 patients. Curr HIV Res 2007; 5: 109-118.
18. Bing EG, Burnam MA, Longshore D et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001; 58: 721-728.
19. Stein MD, Solomon DA, Herman DS, Anderson BJ, Miller I. Depression severity and drug injection HIV risk behaviors. Am J Psychiatry 2003; 160: 1659-1662.
20. National Institutes of Health. Appendix 6. Body Mass Index: How to measure obesity. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The evidence report. NIH Publication #98-4083, pp. 139-140, 1998.
21. Lowe B, Unutzer J, Callahan CM, Perkins AJ, Kroenke K. Monitoring depression treatment outcomes with the patient health questionnaire-9. Med Care 2004; 42: 1194-1201.
22. Beaton DE, Boers M, Wells GA. Many faces of the minimal clinically important difference (MCID): A literature review and directions for future research. Curr Opin Rheumatol 2002; 14: 109-114.
23. Boarts JM, Sledjeski EM, Bogart LM, Delahanty DL. The differential impact of PTSD and depression on HIV disease markers and adherence to HAART in people living with HIV. AIDS Behav 2006; 10: 253-261.
24. Cook JA, Grey D, Burke J et al. Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. Am J Public Health 2004; 94: 1133-1140.
25. Ickovics JR, Hamburger ME, Vlahov D et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV- seropositive women: longitudinal analysis from the HIV epidemiology research study. JAMA 2001; 285: 1466-1474.
26. Mayne TJ, Vittinghoff E, Chesney MA, Barrett DC, Coates TJ. Depressive affect and survival among gay and bisexual men infected with HIV. Arch Intern Med 1996; 156: 2233-2238.
27. Paterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30.
28. Diez-Quevedo C, Rangil T, Sanchez-Planell L, Kroenke K, Spitzer RL. Validation and utility of the patient health questionnaire in diagnosing mental disorders in 1003 general hospital Spanish inpatients. Psychosom Med 2001; 63: 679-686.
29. Justice AC, McGinnis KA, Atkinson JH et al. Psychiatric and neurocognitive disorders among HIV-positive and negative veterans in care: Veterans Aging Cohort Five-Site Study. AIDS 2004; 18 (Suppl. 1): S49-S59.
30. Lowe B, Kroenke K, Herzog W, Grafe K. Measuring depression outcome with a brief self-report instrument: Sensitivity to change of the Patient Health Questionnaire (PHQ-9). J Affect Disord 2004; 81: 61-66.
31. Lowe B, Schenkel I, Carney-Doebbeling C, Gobel C. Responsiveness of the PHQ-9 to psychopharmacological depression treatment. Psychosomatics 2006; 47: 62-67.
32. Martin A, Rief W, Klaiberg A, Braehler E. Validity of the brief patient health questionnaire mood scale (PHQ-9) in the general population. Gen Hosp Psychiatry 2006; 28: 71-77.
33. Spitzer RL, Williams JB, Kroenke K, Hornyak R, McMurray J. Validity and utility of the PRIME-MD patient health questionnaire in assessment of 3000 obstetric-gynecologic patients: The PRIME-MD patient health questionnaire obstetrics-gynecology study. Am J Obstet Gynecol 2000; 183: 759-769.
34. American Psychiatric Association. Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV, 4th edn. Washington, DC: American Psychiatric Association, 1994: P. xxvii.
35. Moyle GJ, Brown S, Lysakova L, Barton SE. Long-term safety and efficacy of poly-l-lactic acid in the treatment of HIV-related facial lipoatrophy. HIV Med 2006; 7: 181-185.